Key result
Perindopril lowers BP without altering serum lipids or apolipoproteins versus placebo.
Why the study?
Does perindopril alter serum lipids and apolipoprotein concentrations in hyperlipidemic patients with mild hypertension?
Population
51 hyperlipidemic patients treated for mild hypertension
Comparison
Perindopril 4 mg as a single morning dose for 6… vs Placebo
Design
RCT, randomized, double-blind
Follow-up
6 weeks
Authors
Loading...
Supports perindopril in mild hypertension with hyperlipidemia; confirms neutral lipid and apolipoprotein effects.
RCT (n=51)
double-blind
randomized
Yes
Does perindopril alter serum lipids and apolipoprotein concentrations in hyperlipidemic patients with mild hypertension?
Perindopril effectively lowers blood pressure in patients with mild hypertension without adversely affecting lipid profiles, making it a suitable antihypertensive for patients with concomitant hyperlipidemia.
Middeke et al. (1994) conducted an RCT in mild hypertension and hyperlipidemia (n=51). Perindopril vs. placebo was evaluated on Serum lipids and apolipoprotein concentrations. Perindopril (4 mg daily) significantly reduced blood pressure from 159/99 to 148/90 mm Hg (p < 0.001) without significantly altering serum lipid or apolipoprotein levels compared with placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: